Home Cart Sign in  
Chemical Structure| 1342278-01-6 Chemical Structure| 1342278-01-6

Structure of RKI-1447
CAS No.: 1342278-01-6

Chemical Structure| 1342278-01-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

RKI-1447 is a potent small molecule inhibitor of ROCK1 and ROCK2, with IC50 of 14.5 nM and 6.2 nM, respectively, and has anti-invasive and antitumor activities.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of RKI-1447

CAS No. :1342278-01-6
Formula : C16H14N4O2S
M.W : 326.37
SMILES Code : O=C(NC1=NC(C2=CC=NC=C2)=CS1)NCC3=CC=CC(O)=C3
MDL No. :MFCD26142658
InChI Key :GDVRVPIXWXOKQO-UHFFFAOYSA-N
Pubchem ID :60138149

Safety of RKI-1447

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P305+P351+P338

Related Pathways of RKI-1447

GPCR
cytoskeleton

Isoform Comparison

Biological Activity

Target
  • ROCK1

    ROCK1, IC50:14.5 nM

  • ROCK2

    ROCK2, IC50:6.2 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Med8a 1 µM 24 hours Inhibited phosphorylation of MLC2, reduced cell proliferation Cancers (Basel). 2019 Dec 26;12(1):73.
UW228-3 1.84 µM 72 hours Inhibited tumorigenic capacity Cancers (Basel). 2019 Dec 26;12(1):73.
D458 3 µM 24 hours Inhibited phosphorylation of MLC2, reduced cell proliferation Cancers (Basel). 2019 Dec 26;12(1):73.
D425 1 µM 24 hours Inhibited phosphorylation of MLC2, reduced cell proliferation Cancers (Basel). 2019 Dec 26;12(1):73.
DAOY 10 µM 24 hours Inhibited phosphorylation of MLC2, reduced cell proliferation Cancers (Basel). 2019 Dec 26;12(1):73.
NIH3T3 cells 1 µM 1 hour Inhibited LPA-induced actin stress fiber formation but not PDGF-induced lamellipodia or bradykinin-induced filopodia formation Cancer Res. 2012 Oct 1;72(19):5025-34.
H1299 human lung cancer cells 100 nM to 10 µM 1 hour Inhibited phosphorylation levels of ROCK substrate MYPT-1 Cancer Res. 2012 Oct 1;72(19):5025-34.
MDA-MB-468 human breast cancer cells 100 nM to 10 µM 1 hour Inhibited phosphorylation levels of ROCK substrates MLC-2 and MYPT-1 Cancer Res. 2012 Oct 1;72(19):5025-34.
MDA-MB-231 human breast cancer cells 100 nM to 10 µM 1 hour Inhibited phosphorylation levels of ROCK substrates MLC-2 and MYPT-1 Cancer Res. 2012 Oct 1;72(19):5025-34.
MSC-4H-FC cells 0.5 µM 24 hours Inhibition of RHO/ROCK signaling, completely abolishing 3D spheroid invasion of MSC-4H-FC cells Neoplasia. 2018 Jan;20(1):44-56.
OCI-AML2 SRSF2 Mut cells 0.5 µM 24 hours RKI-1447 caused G2/M cell-cycle arrest and abnormal spindle formation. iScience. 2024 Mar 6;27(4):109443.
MOLM14 SRSF2 Mut cells 0.5 µM 24 hours RKI-1447 induced mitotic catastrophe, cytoskeleton reorganization, and severe nuclear deformation, preventing cells from completing mitosis. iScience. 2024 Mar 6;27(4):109443.
IPSC-derived HSPCs SRSF2 P95L 3 µM 48 hours RKI-1447 showed higher toxicity to SRSF2 mutant cells. iScience. 2024 Mar 6;27(4):109443.
Panc-1 cells 62.76 µM 72 hours Evaluate the synergistic effect of RKI-1447 with HDAC inhibitors, showing slight synergism in Panc-1 cells Pharmaceuticals (Basel). 2023 Feb 14;16(2):294.
MIA PaCa-2 cells 64.18 µM 72 hours Evaluate the synergistic effect of RKI-1447 with HDAC inhibitors, showing synergism in MIA PaCa-2 cells Pharmaceuticals (Basel). 2023 Feb 14;16(2):294.
786-O 2 µM daily treatment RKI 1447 selectively reduces colony forming ability and colony size in VHL-deficient CC-RCC Oncogene. 2017 Feb 23;36(8):1080-1089.
RCC10 2 µM daily treatment RKI 1447 selectively reduces colony forming ability and colony size in VHL-deficient CC-RCC Oncogene. 2017 Feb 23;36(8):1080-1089.
RCC4 2 µM daily treatment RKI 1447 selectively reduces colony forming ability and colony size in VHL-deficient CC-RCC Oncogene. 2017 Feb 23;36(8):1080-1089.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice 786-OT1 CC-RCC subcutaneous tumor model Intraperitoneal injection 10 mg/kg Daily for 18 days Y-27632 inhibits growth of 786-OT1 CC-RCC tumors Oncogene. 2017 Feb 23;36(8):1080-1089.
MMTV/neu transgenic mice ErbB2 mammary tumor model Intraperitoneal injection 200 mg/kg Once daily for 14 days Inhibited mammary tumor growth, with 60% of tumors being sensitive to RKI-1447, including 35% showing regression and 25% showing growth inhibition Cancer Res. 2012 Oct 1;72(19):5025-34.
NSG mice Primary human SRSF2-mutated AML xenograft model Intraperitoneal injection 50 mg/kg Daily for 21 days RKI-1447 significantly reduced engraftment of SRSF2-mutated AML cells and prolonged mouse survival. iScience. 2024 Mar 6;27(4):109443.
Mice Adult mice Intramuscular injection 80 µl, 10 µM Twice, on the 1st and 3rd day, for 5 days To study the inhibitory effect of RKI-1447 on Lrp4 synaptic expression, it was found that Lrp4 synaptic expression was reduced after RKI-1447 injection. Cell Biosci. 2021 Jun 5;11(1):105
NMRI nu/nu mice D425 subcutaneous xenograft model Intraperitoneal injection 80 mg/kg Daily for ten consecutive days Suppressed tumor growth and proliferation Cancers (Basel). 2019 Dec 26;12(1):73.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.06mL

0.61mL

0.31mL

15.32mL

3.06mL

1.53mL

30.64mL

6.13mL

3.06mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories